Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07677709

A Real-World Exploratory Study on the Sleep-Improving Efficacy of Dong'e Brand Ejiao Yuanjiang

This study employs a real-world design to evaluate the sleep-improving efficacy of Dong'e Brand Ejiao Yuanjiang. A total of 66 participants aged 25-55 will be enrolled and assessed after 60 days of continuous use.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

25 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study

Wenzhou, Zhejiang, 325000, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and non-pregnant, non-lactating females aged 25-55 years (inclusive; subjects exceeding 55 years of age during the trial will not be excluded);
  • Body weight ≥50 kg for males and ≥45 kg for females, with a Body Mass Index (BMI) ranging from 18.5 to 27.9 kg/m² (inclusive of boundary values);
  • Subjects in good general health, with no history of cardiac, hepatic, renal, gastrointestinal, neurological, psychiatric, or metabolic diseases, or any other conditions that, in the investigator's judgment, may affect the study;
  • Signed the informed consent form (ICF) prior to the trial, demonstrating a full understanding of the study content, procedures, and potential adverse reactions, and capable of communicating effectively with the investigators;
  • A score of ≥23 on the Self-Rating Scale of Sleep (SRSS) or ≥10 on the Pittsburgh Sleep Quality Index (PSQI);
  • Self-reported sleep problems, such as difficulty falling asleep or frequent awakenings during sleep;
  • Self-reported post-sleep fatigue or lethargy (e.g., feeling physically tired or mentally sluggish upon waking).

Exclusion criteria

  • Significant abnormalities in laboratory tests (blood routine, liver and kidney function) that, in the investigator's opinion, render the subject unsuitable for participation in the trial;
  • History of esophageal reflux, gastric bleeding, or peptic ulcer disease within 180 days prior to the trial; experiencing heartburn more than once a week; or having undergone any surgical procedure (e.g., cholecystectomy) that may affect the absorption of the study product;
  • History of specific allergies (such as asthma, urticaria, eczema, etc.), allergic constitution (e.g., allergy to two or more drugs, foods, or pollens), or known hypersensitivity to any component of the study product;
  • History of long-term and heavy alcohol consumption, or alcohol consumption habits that, in the investigator's judgment, may affect trial evaluation or subject safety;
  • Pregnant, lactating, or planning to become pregnant;
  • Consumption of sleep aids or neurological regulatory foods and drugs within 90 days prior to the trial;
  • Presence of chronic diseases such as hypertension, hyperlipidemia, or hyperglycemia;
  • History of congenital porphyria metabolism disorders (e.g., acute intermittent porphyria);
  • Smoking more than 3 cigarettes per day; or alcohol consumption of ≥3 standard drinks/day for males and ≥2 standard drinks/day for females;
  • A previous clinical diagnosis of severe sleep disorders or mental debility based on the International Classification of Sleep Disorders, Third Edition (ICSD-3), the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and the Chinese Guidelines for the Diagnosis and Treatment of Insomnia in Adults; or a Self-Rating Scale of Sleep (SRSS) score ≥40;
  • Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this trial.

Treatment and study plan

Dong'e Brand Ejiao Yuanjiang

Dietary Supplement

Dong'e Brand Ejiao Yuanjiang

Placebo

Other

Placebo

Primary outcomes

  1. Score of Self-Rating Scale of Sleep

    Time frame: At baseline (screening/enrollment), and at 30 and 60 days after enrollment

  2. Pittsburgh Sleep Quality Index

    Time frame: At baseline (screening/enrollment), and at 30 and 60 days after enrollment

  3. Number of awakenings

    Time frame: record everyday from the one day after enrollment to the 60th day

    Number of awakenings is recorded from the data of Smart Band

  4. Percentage of light sleep

    Time frame: record everyday from the one day after enrollment to the 60th day

    Percentage of light sleep is recorded from the data of Smart Band

  5. Total Sleep Time

    Time frame: record everyday from the one day after enrollment to the 60th day

    Total Sleep Time is recorded from the data of Smart Band

  6. Percentage of deep sleep

    Time frame: record everyday from the one day after enrollment to the 60th day

    Percentage of deep sleep is recorded from the data of Smart Band

  7. Percentage of REM sleep

    Time frame: record everyday from the one day after enrollment to the 60th day

    Percentage of REM sleep is recorded from the data of Smart Band

  8. Deep sleep continuity

    Time frame: record everyday from the one day after enrollment to the 60th day

    Deep sleep continuity is recorded from the data of Smart Band

Secondary outcomes

  1. Insomnia Severity Index(ISI)

    Time frame: At baseline (screening/enrollment), and at 30 and 60 days after enrollment

  2. Sleep Disorders Rating Scale(SDRS)

    Time frame: At baseline (screening/enrollment), and at 30 and 60 days after enrollment

  3. Fatigue Scale-14

    Time frame: At baseline (screening/enrollment), and at 30 and 60 days after enrollment

  4. Serum γ-aminobutyric acid

    Time frame: At baseline (screening/enrollment), and at 30 and 60 days after enrollment

    Serum γ-aminobutyric acid

  5. Melatonin

    Time frame: At baseline (screening/enrollment), and at 30 and 60 days after enrollment

  6. Cortisol

    Time frame: At baseline (screening/enrollment), and at 30 and 60 days after enrollment

  7. Score of product usage experiences

    Time frame: record weekly over the past 7 days

    a questionnaire about product experiences, max score is 50, min score is 0

Other outcomes

  1. adverse event

    Time frame: through study completion, an average of 2 months

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital of Wenzhou Medical University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 1, 2026
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.